PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.71%
Revenue growth under 50% of MRVL's 13.58%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
8.96%
Gross profit growth at 50-75% of MRVL's 14.70%. Martin Whitman would question if cost structure or brand is lagging.
-912.75%
Negative EBIT growth while MRVL is at 25.23%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-912.75%
Negative operating income growth while MRVL is at 25.23%. Joel Greenblatt would press for urgent turnaround measures.
-1025.69%
Negative net income growth while MRVL stands at 17.65%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-966.67%
Negative EPS growth while MRVL is at 17.86%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-966.67%
Negative diluted EPS growth while MRVL is at 17.86%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.68%
Share count expansion well above MRVL's 0.58%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
-9.15%
Reduced diluted shares while MRVL is at 0.58%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
13562.28%
OCF growth above 1.5x MRVL's 474.06%. David Dodd would confirm a clear edge in underlying cash generation.
420.66%
FCF growth above 1.5x MRVL's 251.32%. David Dodd would verify if the firm’s strategic investments yield superior returns.
240.58%
10Y revenue/share CAGR above 1.5x MRVL's 149.98%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
240.58%
5Y revenue/share CAGR above 1.5x MRVL's 149.98%. David Dodd would look for consistent product or market expansions fueling outperformance.
240.58%
3Y revenue/share CAGR above 1.5x MRVL's 149.98%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
567.31%
10Y OCF/share CAGR above 1.5x MRVL's 106.72%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
567.31%
5Y OCF/share CAGR above 1.5x MRVL's 106.72%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
567.31%
3Y OCF/share CAGR above 1.5x MRVL's 106.72%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-452.26%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-452.26%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-452.26%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
586.03%
10Y equity/share CAGR at 50-75% of MRVL's 843.73%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
586.03%
5Y equity/share CAGR at 50-75% of MRVL's 843.73%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
586.03%
3Y equity/share CAGR at 50-75% of MRVL's 843.73%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.65%
AR growth well above MRVL's 2.75%. Michael Burry fears inflated revenue or higher default risk in the near future.
-28.14%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
0.90%
Positive asset growth while MRVL is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-1.15%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-0.51%
We’re deleveraging while MRVL stands at 196.68%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
0.96%
R&D dropping or stable vs. MRVL's 15.53%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
7.76%
SG&A growth well above MRVL's 0.23%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.